FDA takes action to boost third-party review programme
This article was originally published in Clinica
The US FDA last week more than quadrupled the number of products eligible for review by outside experts to encourage greater participation in its third-party review programme. The agency announced in an updated guidance on the little-used programme that it was increasing the number of eligible third-party products from 154 to all 695 products allowed by law.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.